Loading...

Andrew Kader

TitleClinical Professor
InstitutionUniversity of California San Diego
DepartmentUrology
Address9500 Gilman Drive #0987
La Jolla CA 92093
Phone858-822-7874
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. A. Karim Kader is one of the most experienced surgeons in the United States performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He received his undergraduate, doctorate of philosophy, and medical degrees from the University of British Columbia and completed his urology residency at the University of Toronto. He completed a urologic oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Kader holds several patents for genetic discoveries that hold significant promise for early detection and prevention of prostate cancer. He is the principal investigator for numerous clinical research projects and has published extensively. His research interests include genetic markers of risk and outcome in urologic cancer.


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 Apr 17. PMID: 29891203.
      View in: PubMed
    2. Leivo MZ, Sahoo D, Hamilton Z, Mirsadraei L, Shabaik A, Parsons JK, Kader AK, Derweesh I, Kane C, Hansel DE. Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. Am J Surg Pathol. 2018 Jan; 42(1):e1-e10. PMID: 29076872.
      View in: PubMed
    3. Gaylis FD, Choi JE, Hamilton Z, Dato P, Cohen E, Calabrese R, Prime H, Rosenbaum A, Kader AK. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. Urol Oncol. 2017 Nov; 35(11):663.e1-663.e7. PMID: 28736250.
      View in: PubMed
    4. Brunsing RL, Schenker-Ahmed NM, White NS, Parsons JK, Kane C, Kuperman J, Bartsch H, Kader AK, Rakow-Penner R, Seibert TM, Margolis D, Raman SS, McDonald CR, Farid N, Kesari S, Hansel D, Shabaik A, Dale AM, Karow DS. Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. J Magn Reson Imaging. 2017 Feb; 45(2):323-336. PMID: 27527500.
      View in: PubMed
    5. Kader AK, Liss MA, Trottier G, Kim ST, Sun J, Zheng SL, Chadwick K, Lockwood G, Xu J, Fleshner NE. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk. Urology. 2015 Jan; 85(1):165-70. PMID: 25530379.
      View in: PubMed
    6. Mahan MA, Kader AK, Brown JM. Robot-assisted triple neurectomy for iatrogenic inguinal pain: a technical note. Acta Neurochir (Wien). 2014 Jan; 156(1):171-5. PMID: 24026228.
      View in: PubMed
    7. Lu Y, Sun J, Kader AK, Kim ST, Kim JW, Liu W, Sun J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J. Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Prostate. 2012 Mar; 72(4):376-85. PMID: 21671247; PMCID: PMC3366362.
    8. Pettus JA, Werle DM, Saunders W, Hemal A, Kader AK, Childs D, Zagoria RJ. Percutaneous radiofrequency ablation does not affect glomerular filtration rate. J Endourol. 2010 Oct; 24(10):1687-91. PMID: 20818985.
      View in: PubMed